Targeting Ovarian Cancer Cells Overexpressing CD44 with Immunoliposomes Encapsulating Glycosylated Paclitaxel

Paclitaxel (PTX) is one of the front-line drugs approved for the treatment of ovarian cancer. However, the application of PTX is limited due to the significant hydrophobicity and poor pharmacokinetics. We previously reported target-directed liposomes carrying tumor-selective conjugated antibody and...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Int J Mol Sci
Glavni autori: Khayrani, Apriliana Cahya, Mahmud, Hafizah, Oo, Aung Ko Ko, Zahra, Maram H., Oze, Miharu, Du, Juan, Alam, Md Jahangir, Afify, Said M., Quora, Hagar A. Abu, Shigehiro, Tsukasa, Calle, Anna Sanchez, Okada, Nobuhiro, Seno, Akimasa, Fujita, Koki, Hamada, Hiroki, Seno, Yuhki, Mandai, Tadakatsu, Seno, Masaharu
Format: Artigo
Jezik:Inglês
Izdano: MDPI 2019
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6429518/
https://ncbi.nlm.nih.gov/pubmed/30818864
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms20051042
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items